Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)

Inclusion criteria

• Male or female patients aged between 18 to 65 years.
• Have an acute illness (less than or equal to 7 days duration) with any of the following signs and symptoms consistent with a lower respiratory tract infection (new or worsening):

• Fever (body temperature > 38.0 °C (100.4 °F) measured orally)
• Shortness of breath
• New onset or increased cough with or without sputum production.
• Chest pain.
• Have radiographically documented bacterial pneumonia:

• Infiltrates in a unilateral, lobar distribution
• Diffuse opacities or white condensed area
• The alveoli fill with white inflammatory fluid

Exclusion criteria

• Patients with severe pneumonia (Clinical & Radiological Assessment)
• Patients with suspicion of viral pneumonia (bilateral, patchy opacities, etc., in chest radiography.)
• Patients with suspicion of nosocomial pneumonia, aspiration pneumonia, etc.
• History of hypersensitivity, known or suspected contraindications, or intolerance to any of the study drugs.
• Intake of an antibiotic within the last 48 hours before study admission.
• History of hospitalization within the last 28 days.
• Patients in pregnancy and lactational state.
• Patients with Renal impairment (screening eGFR < 30mL/min).
• Significant hepatic impairment (Alanine aminotransferase > three times the upper limit of normal).
• Serious diseases that affect the immune system, such as Acquired Immunodeficiency Syndrome (AIDS), cancer, etc.
• Patients who are taking steroid medications, at least 20 mg daily dose of prednisolone (or equivalent doses of other glucocorticoids).
• Patients who are accepting chemotherapy or anti-cancer therapy or plan to receive such treatment during the trial or six months prior to enrollment.
• Had epilepsy, stroke, or other central nervous system disorders or uncontrolled psychiatric history.